Greg Findlay

Qualifications and history

  • 2009 Research Technician, Immune Disease Institute at Harvard Medical School, Boston, USA
  • 2012 Entered Medical Scientist Training Program, University of Washington, Seattle, USA
  • 2016 Awarded Ruth Kirschstein Fellowship from the National Cancer Institute, National Institutes of Health
  • 2018 PhD, Genome Sciences, University of Washington, Seattle, USA
  • 2020 MD, School of Medicine, University of Washington, Seattle, USA
  • 2020 Group Leader, the Francis Crick Institute, London, UK

Greg received his bachelor’s degree in biology from Carleton College in 2009, before working as a research technician with Drs. Anjana Rao and Tomas Kirchhausen at Harvard Medical School studying cellular signaling pathways of the immune system.

In 2012, Greg entered the Medical Scientist Training Program at the University of Washington in Seattle. He was awarded an ARCS Foundation scholarship in 2014, as well as a Ruth L. Kirschstein fellowship from the National Institutes of Health in 2016 to develop new genome editing methods to study mutations in cancer predisposition genes.

He completed his PhD in Genome Sciences in 2018 under the supervision of Dr. Jay Shendure. During this time, Greg led the development of several novel high-throughput genome editing methods. These included Saturation Genome Editing, which he employed to study thousands of mutations in BRCA1, ScanDel, a method for engineering large deletions in multiplex, and GESTALT, a CRISPR/Cas9-based lineage tracing technique. In 2019, Greg received the Innovation in Technology Award from the Western Association of Graduate Schools and Proquest for his PhD work.

Greg earned his MD from the University of Washington School of Medicine in 2020 before joining the Crick as a Group Leader shortly after.

Displaying 1 - 11 of 11
Last updated : 25 November 2020 02:37